Angiogenesis in cancer diseases
Keywords:
cancer, VEGF, antiangiogenic therapy, pro- and antiangiogenic factorsAbstract
The growth of tumor depends on the access to nutrients and oxygen. This is done with the use of blood vessels. They provide essential nutrients to cancer cells and also play a significant role in the formation of metastases. Cancer cells have the ability to produce their own system of blood vessels through angiogenesis. Factors involved in the regulation of formation of a new vascular system can be classified into two groups of pro-and antiangiogenic ones. Stimulation of angiogenesis occurs when the number of proangiogenic factors predominates. The main proangiogenic factor is vascular endothelial growth factor VEGF, stimulating cell division, migration and proliferation of endothelial cells. Inhibition of VEGF and hence angiogenesis suppression raises hope for improvement of cancer treatment. Antiangiogenic therapy currently raises wide interest and tests of antiangiogenic drugs are still ongoing and provide valuable information on how to inhibit this process.
Downloads
References
Zielonka TM. Angiogeneza – Część I. Mechanizm powstawania nowych naczyń krwionośnych. Alergia Astma Immunologia 2003; 8: 169-174.
Grosicki S, Grosicka A, Hołowiecki J. Kliniczne znaczenie angiogenezy i czynników ją modyfikujących w onkohematologii. Wiadomości lekarskie 2007; 60: 39-41.
Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases and chronic Inflammation. Pharmacol Reviews 2000; 52: 237-268.
Olbryt M, Szala S. Białkowe inhibitory angiogenezy w terapii nowotworów. Współczesna Onkologia 2005; 9: 48-52.
Patel-Hett S, D'Amore PA. Signal transduction in vasculogenesis and developmental angiogenesis. Int J Dev Biol. 2011; 55(4-5): 353-363.
Wiśniewski T, Makarewicz R, Ziółkowska E, Rystok D, Żekanowska E. Angiogeneza nowotworowa – mechanizmy, czynniki regulatorowe, leki. Onkologia Info 2009; 5: 172-178.
Wnuczko K, Szczepański M. Śródbłonek – charakterystyka i funkcje. Pol. Merk. Lek. 2007; XXIII, 133: 60-65.
Napoli C, Giordano A, Casamassimi A, Pentimalli F, Ignarro LJ, De Nigris F. Directed in vivo angiogenesis assay and the study of systemic neoangiogenesis in cancer. Int J Cancer. 2011; 128(7): 1505-8.
Mizia-Malarz A, Sobol G, Woś H. Angiogeneza w przewlekłych schorzeniach zapalnych i nowotworowych. Pol. Merk. Lek. 2008; XXIV: 185-189.
Szostakiewicz B, Dziadziuszko R, Jassem J. Perspektywy zastosowania inhibitorów angiogenezy w leczeniu nie drobnokomórkowego raka płuca. Współczesna Onkologia 2003; 7: 668-674.
Carmeliet P. Angiogenesis in health and disease. Nat. Med. 2003; 9(6): 653-660.
Cierniewski CS. regulacja angiogenezy – nowa broń w onkologii. Biol. Molek. 2006; 1(5): 20-22.
Xu L, Kanasaki K, Kitada M, Koya D. Diabetic angiopathy and angiogenic defects. Fibrogenesis Tissue Repair 2012; 5(1): 13
Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 63: 89-95.
Giordano FJ. Angiogenesis: mechanisms, modulation and target imaging. J Nucl Cardiol 1999; 6: 664-671.
Juczewska M i wps. Udział komórek tucznych w angiogenezie. Postępy Biologii Komórki 2000; 27: 343-358.
Denekamp J. The tumor microcirculation as a target in cancer therapy: a clear perspective. Eur J Clin Invest 1999; 29: 733-736.
Swidzińska E, Naumnik W, Chyczewska E. Angiogeneza i neoangiogeneza – znaczenie w raku płuca i innych nowotworach. Pneumonol. Alergol. Pol. 2006; 74: 414-420.
Lirdprapamongkol K, Chiablaem K, Sila-Asna M, Surarit R, Bunyaratvej A, Svasti J. Exploring stemness gene expression and vasculogenic mimicry capacity in well- and poorly-differentiated hepatocellular carcinoma cel lines. Biochem Biophys Res Commun. 2012; 422(3): 429-435.
Hendrix MJ, Seftor EA, Hess AR i wsp. Vasculogenic mimicry and tumour cell plasticity: lessons from melanoma. Nat Rev Cancer 2003; 3: 411-421.
Wong ML, Prawira A, Kaye AH, Hovens CM. Tumor angiogenesis: its mechanism and therapeutic implications in malignant gliomas. J Clin Neurosci. 2009; 16(9): 1119-1130.
Cox G i wsp. Angiogenesis and non-small cell lung cancer. Lung Cancer 2000; 27: 81-100.
Gaitskell K, Martinek I, Bryant A, Kehoe S, Nicum S, Morrison J. Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev. 2011; 9.
Wagner AD, Thomssen C, Haerting J, Unverzagt S. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database Syst Rev. 2012; 7.
Gerber HP, Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med 2003; 81: 20-31.
Martens T, Laabs Y, Günther HS, Kemming D, Zhu Z, Witte L, Hagel C, Westphal M, Lamszus K. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2. Clin Cancer Res. 2008; 14(17): 5447-5458.
Ferrara N. Molecular and Biological properties of vascular endothelial growth factor. J Mol Med 1999; 77; 527-543.
Zhang Y, Zhang N, Dai B, Liu M, Sawaya R, Xie K, Huang S. FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. Cancer Res. 2008; 68(21): 8733-8742.
Jain RK. Normalization of tumor vasculature: an emerging view of anti-angiogenic therapy. Science 2005; 307: 58-62.
Kamat A, Rajoria S, George A, Suriano R, Shanmugam A, Megwalu U, Prakash PB, Tiwari R, Schantz S. Estrogen-mediated angiogenesis in thyroid tumor microenvironment is mediated through VEGF signaling pathways. Arch Otolaryngol Head Neck Surg. 2011; 137(11):
-1153.
Carrol VA, Binder BR. The role of the plasminogen activation system in cancer. Semin. Thromb. Hemost. 1999; 25: 183–197.
Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocrine Rev. 2004; 25: 581-611.
Ferrara N, Mass RD, Campa C i wsp. Targeting VEGF-A to treat cancer and age-related macular degeneration. Ann. Rev. Med. 2006; 58: 491-504.
Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368-4380.
Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res. 2009; 15(14): 4589-4599.
Dvorak HF. Angiogenesis: update 2005. J. Thromb. Haemost. 2005; 3: 1835-1842.
Verpelli C, Bertani G, Cea V, Patti M, Bikfalvi A, Bello L, Sala C. Anti-angiogenic therapy induces integrin-linked kinase 1 up-regulation in a mouse model of glioblastoma. PLoS One. 2010; 5(10):e13710.
Rahimi N. Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials. Exp. Eye Res. 2006; 83: 1005-1016.
Li C, Liu B, Dai Z, Tao Y. Knockdown of VEGF receptor-1 (VEGFR-1) impairs macrophage infiltration, angiogenesis and growth of clear cell renal cell carcinoma (CRCC). Cancer Biol Ther. 2011; 12(10): 872-880. Scadden DT. Cancer stem cells refined. Nat. Immunol. 2004; 5: 701-703.
Zeng H, Dvorak HF, Mukhopadhyay D. Vascular permeability factor/vascular endothelial growth factor (VEGF) receptor-1 downregulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase- dependent pathways. J. Biol. Chem. 2001; 276: 26969–26979.
Dikov MM, Ohm JE, Ray N i wsp. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J. Immunol. 2005; 174: 215-222.
Hitsuaka S, Maru Y, Okada A i wsp. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth receptor-1) in pathological angiogenesis. Cancer Res. 2001; 61: 1207–1213.
Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res. 2006; 12: 5018-5022.
Holmqwist K, Cross MJ, Rolny C i wsp. The adapter protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J. Biol. Chem. 2004; 279: 22267–22275.
Huang J, Kontos CD. PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects. J. Biol. Chem. 2002; 277: 10760–10766.
Lelievre E, Bourbon PM, Duan LJ i wsp. Deficiency in the p110 subunit of PI3-kinase results in diminished Tie-2 expression and Tie2-/- like vascular defects in mice. Blood 2005; 105: 3935–3938.
Matsumoto T, Bohman S, Dixelius J i wsp. VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. EMBO J. 2005; 24: 2342–2353.
Singh AJ, Meyer RD, Band H i wsp. The carboxyl terminus of VEGFR-2 is required for PKC-mediated down-regulation. Mol. Biol. Cell 2005; 16: 2106–2118.
Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, Thorsen F, Taxt T, Bartos M, Jirik R, Miletic H, Wang J, Stieber D, Stuhr L, Moen I, Rygh CB, Bjerkvig R, Niclou SP. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA. 2011; 108(9): 3749-3754.
Banyś A, Bułaś L, Długosz E, Szulc-Musiał B, Jankowski A. Angiogeneza w chorobie nowotworowej. Patofizjologia 2009; 65: 247-250.
Bareschino MA, Schettino C, Colantuoni G, Rossi E, Rossi A, Maione P, Ciardiello F, Gridelli C. The role of antiangiogenetic agents in the treatment of breast cancer. Curr Med Chem. 2011; 18(33): 5022-5032.
Rak J. Onkogeny jako modyfikatory procesów naczyniowych w nowotworach. Nowotwory 2006; 56: 57-79.
Onishi M, Ichikawa T, Kurozumi K, Date I. Angiogenesis and invasion in glioma. Brain Tumor Pathol. 2011; 28(1): 13-24.
Cea V, Sala C, Verpelli C. Antiangiogenic Therapy for Glioma. Journal of Signal Transduction 2012; 10.1155/2012/483040.
Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin. Oncol. 2004; 31: 2-11.
Adamkiewicz-Drożyńska E, Balcerska A, Stefanowicz J, Bień E. Wczoraj, dziś i jutro terapii antyangiogennej. Medycyna Wieku Rozwojowego 2008; XII, 4, cz. II: 995-1000.
Small AC, Oh WK. Bevacizumab treatment of prostate cancer. Expert Opin Biol Ther. 2012.
Croom KF, Dhillon S. Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer. Drugs 2011; 71(16): 2213-2229.
Dobrek Ł, Szcześniak P, Thor P i wsp. Aktualne kierunki w poszukiwaniu nowych leków przeciwnowotworowych. Geriatria 2008; 2: 37-46.
Lorusso V. Bevacizumab in the treatment of HER2-negative breast cancer. Biologics 2008; 2(4): 813-821.
Bałan BJ. Angiogeneza – problem na mierę XXI wieku. Nowa Medycyna 2000; 4.
Lamy S, Akla N, Ouanouki A, Lord-Dufour S, Béliveau R. Diet- derived polyphenols inhibit angiogenesis by modulating the interleukin-6/STAT3 pathway. Exp. Cell Res. 2012; 318 (13): 1586-1596.
Albini A, Tosetti F, Li VW, Noonan DM, Li WW. Cancer prevention by targeting angiogenesis. Nat. Rev. Clin. Oncol. 2012; 120.
Kubota Y.tumor Angiogenesis and Anti-angiogenic Therapy. Keio J Med. 2012; 61(2): 47-56.
Szala S. Rola leków antyangiogennych w wielolekowej terapii nowotworów. Onkol. Prak. Klin. 2008; 4:1-7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2012 Medical Journal of the Rzeszow University and the National Medicines Institute, Warsaw
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
